BNTX
Price
$87.65Alerts
Change
+$0.44 (+0.50%)
Updated
Nov 11 closing price
Capitalization
21.98B
138 days until earnings call
Intraday BUY SELL Signals
CLDI
Price
$0.67Alerts
Change
-$0.01 (-1.47%)
Updated
Nov 11, 03:54 PM (EDT)
Capitalization
1.81M
Earnings call today
Intraday BUY SELL Signals
Interact to see
Advertisement

BNTX vs CLDI

BNTX vs CLDI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BNTX vs. CLDI commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BNTX is a Hold and CLDI is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BNTX with price predictions
Nov 11, 2026

BNTX's RSI Indicator ascending out of oversold territory

The RSI Oscillator for BNTX moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 23 of the 28 cases the stock moved higher. This puts the odds of a move higher at 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 37 of 60 cases where BNTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.

The Moving Average Convergence Divergence (MACD) for BNTX just turned positive on October 30, 2026. Looking at past instances where BNTX's MACD turned positive, the stock continued to rise in 34 of 45 cases over the following month. The odds of a continued upward trend are 76%.

Following a +2.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNTX advanced for three days, in 180 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

BNTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BNTX as a result. In 77 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.

The 50-day moving average for BNTX moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

The Aroon Indicator for BNTX entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.238) is normal, around the industry mean (3.498). P/E Ratio (-13.042) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.046) is also within normal values, averaging (9.059). Dividend Yield (0.097) settles around the average of (130.981) among similar stocks. P/S Ratio (7.764) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 38 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. BNTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for CLDI with price predictions
Nov 11, 2026

CLDI's RSI Indicator recovers from oversold territory

The RSI Oscillator for CLDI moved out of oversold territory on November 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 29 of the 44 cases the stock moved higher. This puts the odds of a move higher at 66%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 33 of 71 cases where CLDI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 46%.

The Moving Average Convergence Divergence (MACD) for CLDI just turned positive on October 30, 2026. Looking at past instances where CLDI's MACD turned positive, the stock continued to rise in 20 of 44 cases over the following month. The odds of a continued upward trend are 45%.

Following a +7.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLDI advanced for three days, in 67 of 136 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.

CLDI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLDI as a result. In 59 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLDI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for CLDI entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.577) is normal, around the industry mean (3.498). P/E Ratio (-0.019) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. CLDI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLDI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
BNTX: Fundamental Ratings
BNTX
OUTLOOK RATING
1..100
20
VALUATION
overvalued / fair valued / undervalued
1..100
12
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
93
PRICE GROWTH RATING
1..100
70
P/E GROWTH RATING
1..100
38
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BNTXCLDI
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 1 day ago
66%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
62%
Bullish Trend 1 day ago
46%
Momentum
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
75%
MACD
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
45%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 14 days ago
68%
Bullish Trend 3 days ago
49%
Declines
ODDS (%)
Bearish Trend 9 days ago
78%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
64%
Aroon
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (BNTX: $87.65 vs. CLDI: $0.68)
Brand notoriety: BNTX and CLDI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BNTX: 86% vs. CLDI: 22%
Market capitalization -- BNTX: $21.98B vs. CLDI: $1.81M
BNTX [@Biotechnology] is valued at $21.98B. CLDI’s [@Biotechnology] market capitalization is $1.81M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BNTX’s FA Score shows that 1 FA rating(s) are green while CLDI’s FA Score has 0 green FA rating(s).

  • BNTX’s FA Score: 1 green, 4 red.
  • CLDI’s FA Score: 0 green, 5 red.
According to our system of comparison, BNTX is a better buy in the long-term than CLDI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BNTX’s TA Score shows that 5 TA indicator(s) are bullish while CLDI’s TA Score has 5 bullish TA indicator(s).

  • BNTX’s TA Score: 5 bullish, 4 bearish.
  • CLDI’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, BNTX is a better buy in the short-term than CLDI.

Price Growth

BNTX (@Biotechnology) experienced а -3.36% price change this week, while CLDI (@Biotechnology) price change was -7.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.

Reported Earning Dates

BNTX is expected to report earnings on Mar 30, 2027.

CLDI is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (-0.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

BNTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BNTX has been loosely correlated with MRNA. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if BNTX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BNTX
1D Price
Change %
BNTX100%
+0.50%
MRNA - BNTX
60%
Loosely correlated
-0.85%
CRSP - BNTX
47%
Loosely correlated
+1.33%
NVAX - BNTX
44%
Loosely correlated
-2.16%
AXON - BNTX
43%
Loosely correlated
+4.26%
MRVI - BNTX
42%
Loosely correlated
-2.04%
More

CLDI and

Correlation & Price change

A.I.dvisor tells us that CLDI and PROK have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLDI and PROK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDI
1D Price
Change %
CLDI100%
-1.29%
PROK - CLDI
32%
Poorly correlated
+1.80%
BNTX - CLDI
31%
Poorly correlated
+0.50%
RYTM - CLDI
29%
Poorly correlated
-1.57%
MBIO - CLDI
29%
Poorly correlated
-3.06%
CLDX - CLDI
29%
Poorly correlated
-1.63%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NXL1.590.12
+8.16%
Nexalin Technology Inc.
PINS19.230.28
+1.48%
Pinterest
RDAC11.230.06
+0.49%
Rising Dragon Acquisition Corp.
SRCE87.71-0.14
-0.16%
1st Source Corp
BAK1.10-0.01
-0.90%
Braskem SA